We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In the annals of biopharma M&A the first quarter of 2018 will go down as another strong start to the year, with $34bn in deals achieved without the benefit of a single mega-merger.